Germany-based Rigontec, which focuses on RIG-I targeting RNA therapeutics, has raised 15 million euros in Series A funding. The investors included Boehringer Ingelheim Venture Fund, Forbion Capital Partners, High-Tech Gründerfonds, Sunstone Capital and Wellington Partners Life Sciences.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: